Patent SG-11201900468Y-A (SG)
Title: Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
Inventor: ATTAR RICARDO
IPC: C07K16/28
Filed: 2017-07-20
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property - C.-- - .` Organization 1111111111101110101011111 01111101 0 11111010 110111111101 111111111111111 0111111 International Bureau (10) International Publication Number 03 (43) International Publication Date .../ WO 2018/017786 A3 25 January 2018 (25.01.2018) WI P0 I P C T (51) International Patent Classification: (72) Inventor; and C07K 16/28 (2006.01) A61P 35/02 (2006.01) (71) Applicant: ATTAR, Ricardo [US/US]; 1400 McKean A61K 39/395 (2006.01) Road, Spring House, Pennsylvania 19477 (US). (21) International Application Number: (72) Inventors: CHIN, Diana; 1400 McKean Road, Spring PCT/US2017/042982 House, Pennsylvania 19477 (US). EDAVETTAL, Suzanne; 1400 McKean Road, Spring House, Pennsylva- (22) International Filing Date: 20 July 2017 (20.07.2017) nia 19477 (US). GAUDET, Francois; 3210 Merryfield Row, La Jolla, 92121 (UA). LI, Yingzhe; 1400 McKean (25) Filing Language: English Road, Spring House, Pennsylvania 19477 (US). LUISTRO, Leopoldo; 1400 McKean Road, Spring House, Pennsyl- (26) Publication Language: English vania 19477 (US). MAJEWSKI, Nathan; 1400 McKean (30) Priority Data: Road, Spring House, Pennsylvania 19477 (US). MEN- 62/364,811 20 July 2016 (20.07.2016) US DONCA, Mark; 1400 McKean Road, Spring House, Penn- sylvania 19477 (US). PILLARISETTI, Kondandaram; (71) Applicant: JANSSEN PHARMACEUTICA NV 1400 McKean Road, Spring House, Pennsylvania 19477 [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (US). TEPLYAKOV, Alexey; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). TORNETTA, Mark; _ (54) Title: ANTI- GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, USES THEREOF AND = = Figure 1 = 35000 — 30000 Ei GP RC5D Cells lug/ml = • 293F lOugjmi e 4) 25000 • 293F tug/ml — O = — °.' d 20000 = = 2 is000 0 D ii _ C 10(100 = 2 — = 2 5000 II—IL e. .. l€11. = .4 I , 0 ,, .—, . vi vi •-.1 EN r.s EN = b 11 V_) :2 ) :3 2 i J .-1 ,,-„ 72. n A Ai 6 .T- . v 2. c N A o ,R, :' , „: L 'i ',' y j 0 t . 9 0 0 0 0 5 0 ,., T 'D ID 6 0 ID = = — = — _ = M Vr; (57) : Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable * t of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or anti- IN N gen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, meth- 1-1 ods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor --.., © GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; Ot or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a C 1-1 GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein. ei O [Continued on next page] WO 2018/017786 A3 MUNRO DOI 01011MERIONIMMEMEROMEfin 1400 McKean Road, Spring House, Pennsylvania 19477 (US). (74) Agent: SHIRTZ, Joseph F. et al.; JOHNSON & JOHNSON, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(U)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) (88) Date of publication of the international search report: 01 March 2018 (01.03.2018)